The 21st Dutch German Joint Meeting of the Molecular Cardiology Working Groups
Focus on cardiac disease mechanisms and tailored therapies
In the coming decades, we anticipate significant advancements in cardiac disease therapy, particularly in the treatment of heart failure. These advancements will shift from a one-size-fits-all approach to more personalized and tailored therapies. The recent recognition that heart failure with preserved ejection fraction (HFpEF) necessitates different therapeutic strategies compared to heart failure with reduced ejection fraction (HFrEF) serves as an excellent example of the evolving landscape of treatment.
Consequently, our focus will be on exploring the diverse underlying causes of cardiac diseases, such as metabolic factors, inflammation, atherosclerosis and genetic predispositions, which contribute to the development of specific forms of cardiac disease. Additionally, we will address the growing importance of sex differences in both research and treatment, acknowledging that males and females may benefit from more tailored approaches.
Our central theme will revolve around in-depth discussions of disease mechanisms specific to cardiac conditions and the identification of novel therapeutic strategies. By delving into these topics, we aim to contribute to the advancement of tailored therapies that offer improved outcomes for patients with cardiac diseases.